Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...
The most common side effects of INVEGA HAFYERA® include: injection site reactions, weight gain, headache, upper respiratory ...
Medical Xpress on MSN7d
People with schizophrenia show distinct brain activity when faced with conflicting information, research findsScientists have known for decades that the classic symptoms of schizophrenia, such as jumping to conclusions or difficulty ...
By Puyaan Singh and Bhanvi Satija (Reuters) -AbbVie shares fell over 12% on Monday after an experimental schizophrenia drug ...
Psychedelics have been growing in popularity across North America for recreational and therapeutic use, with celebrities like ...
A new study from ICES and University of Ottawa reveals a 21-fold increase in schizophrenia risk following emergency visits ...
HealthDay on MSN20h
Psychedelics Like Psilocybin, MDMA Tied to Higher Odds for SchizophreniaPeople are at higher risk of schizophrenia if they indulge in psychedelic drugs, a new study warns. Patients who land in the ER following hallucinogen use have a 21-fold higher risk of developing ...
ED visits related to hallucinogen use are linked to a 21-fold increased risk of schizophrenia spectrum disorder, results of a ...
AbbVie reports disappointing mid-stage data for its schizophrenia drug. Jason Snipe of Odyssey Capital still likes AbbVie ...
AbbVie Inc. shares fell the most in more than four years after two mid-stage trials of its drug to treat schizophrenia failed ...
The shocking failure of AbbVie’s emraclidine has investors questioning the Big Pharma’s long-term neuroscience strategy, ...
Shares of AbbVie (ABBV) are sliding on Monday after the company’s drug candidate for schizophrenia failed to meet the key goal in two ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback